CN115243763A - 治疗进行性骨化性纤维发育不良 - Google Patents

治疗进行性骨化性纤维发育不良 Download PDF

Info

Publication number
CN115243763A
CN115243763A CN202180019312.5A CN202180019312A CN115243763A CN 115243763 A CN115243763 A CN 115243763A CN 202180019312 A CN202180019312 A CN 202180019312A CN 115243763 A CN115243763 A CN 115243763A
Authority
CN
China
Prior art keywords
activin
antibody
lesions
reduction
human subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180019312.5A
Other languages
English (en)
Chinese (zh)
Inventor
A·伊科诺米季斯
E·福尔里奥·内托
D·冈萨雷斯·特罗特
G·赫尔曼
A·兰金
S·梅利斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Regeneron Pharmaceuticals Inc
Original Assignee
Regeneron Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharmaceuticals Inc filed Critical Regeneron Pharmaceuticals Inc
Publication of CN115243763A publication Critical patent/CN115243763A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Endocrinology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Chemical Or Physical Treatment Of Fibers (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Diaphragms For Electromechanical Transducers (AREA)
CN202180019312.5A 2020-01-08 2021-01-08 治疗进行性骨化性纤维发育不良 Pending CN115243763A (zh)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202062958448P 2020-01-08 2020-01-08
US62/958,448 2020-01-08
US202063076691P 2020-09-10 2020-09-10
US63/076,691 2020-09-10
US202063081428P 2020-09-22 2020-09-22
US63/081,428 2020-09-22
PCT/US2021/012598 WO2021142191A1 (en) 2020-01-08 2021-01-08 Treatment of fibrodysplasia ossificans progressiva

Publications (1)

Publication Number Publication Date
CN115243763A true CN115243763A (zh) 2022-10-25

Family

ID=74550734

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180019312.5A Pending CN115243763A (zh) 2020-01-08 2021-01-08 治疗进行性骨化性纤维发育不良

Country Status (12)

Country Link
US (2) US12344665B2 (enExample)
EP (1) EP4087652A1 (enExample)
JP (2) JP7802672B2 (enExample)
KR (1) KR20220139886A (enExample)
CN (1) CN115243763A (enExample)
AU (1) AU2021205929A1 (enExample)
BR (1) BR112022013589A2 (enExample)
CA (1) CA3164168A1 (enExample)
CL (1) CL2022001861A1 (enExample)
IL (1) IL294611B1 (enExample)
MX (1) MX2022008494A (enExample)
WO (1) WO2021142191A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3235627A1 (en) * 2021-10-18 2023-04-27 Byomass Inc. Anti-activin a antibodies, compositions and uses thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170211070A1 (en) * 2014-03-31 2017-07-27 Sumitomo Dainippon Pharma Co., Ltd. Prophylactic Agent and Therapeutic Agent for Fibrodysplasia Ossificans Progressiva
CN107106648A (zh) * 2014-09-12 2017-08-29 瑞泽恩制药公司 进行性骨化性纤维发育不良的治疗

Family Cites Families (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH652145A5 (de) 1982-01-22 1985-10-31 Sandoz Ag Verfahren zur in vitro-herstellung von hybridomen welche humane monoklonale antikoerper erzeugen.
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4634666A (en) 1984-01-06 1987-01-06 The Board Of Trustees Of The Leland Stanford Junior University Human-murine hybridoma fusion partner
US4980286A (en) 1985-07-05 1990-12-25 Whitehead Institute For Biomedical Research In vivo introduction and expression of foreign genetic material in epithelial cells
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
JP3101690B2 (ja) 1987-03-18 2000-10-23 エス・ビィ・２・インコーポレイテッド 変性抗体の、または変性抗体に関する改良
US5567584A (en) 1988-01-22 1996-10-22 Zymogenetics, Inc. Methods of using biologically active dimerized polypeptide fusions to detect PDGF
US6018026A (en) 1988-01-22 2000-01-25 Zymogenetics, Inc. Biologically active dimerized and multimerized polypeptide fusions
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5225538A (en) 1989-02-23 1993-07-06 Genentech, Inc. Lymphocyte homing receptor/immunoglobulin fusion proteins
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
EP1690935A3 (en) 1990-01-12 2008-07-30 Abgenix, Inc. Generation of xenogeneic antibodies
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
US5270163A (en) 1990-06-11 1993-12-14 University Research Corporation Methods for identifying nucleic acid ligands
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5874299A (en) 1990-08-29 1999-02-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
ES2246502T3 (es) 1990-08-29 2006-02-16 Genpharm International, Inc. Animales no humanos transgenicos capaces de producir anticuerpos heterologos.
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5858657A (en) 1992-05-15 1999-01-12 Medical Research Council Methods for producing members of specific binding pairs
US5871907A (en) 1991-05-15 1999-02-16 Medical Research Council Methods for producing members of specific binding pairs
EP0590058B1 (en) 1991-06-14 2003-11-26 Genentech, Inc. HUMANIZED Heregulin ANTIBODy
US5582981A (en) 1991-08-14 1996-12-10 Gilead Sciences, Inc. Method for identifying an oligonucleotide aptamer specific for a target
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
JPH07503132A (ja) 1991-12-17 1995-04-06 ジェンファーム　インターナショナル，インコーポレイティド 異種抗体を産生することができるトランスジェニック非ヒト動物
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
US5756291A (en) 1992-08-21 1998-05-26 Gilead Sciences, Inc. Aptamers specific for biomolecules and methods of making
ATE199392T1 (de) 1992-12-04 2001-03-15 Medical Res Council Multivalente und multispezifische bindungsproteine, deren herstellung und verwendung
DE614989T1 (de) 1993-02-17 1995-09-28 Morphosys Proteinoptimierung Verfahren für in vivo Selektion von Ligandenbindende Proteine.
US5914349A (en) 1994-01-10 1999-06-22 Teva Pharmaceutical Industries, Ltd. Compositions containing and methods of using 1-aminoindan and derivatives thereof and process for preparing optically active 1-aminoindan derivatives
WO1997042317A1 (en) 1996-05-07 1997-11-13 T Cell Sciences, Inc. APTAMERS FOR COMPLEMENT PROTEIN C3b
US5834597A (en) 1996-05-20 1998-11-10 Protein Design Labs, Inc. Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same
TW589189B (en) 1997-08-04 2004-06-01 Scras Kit containing at least one double-stranded RNA combined with at least one anti-viral agent for therapeutic use in the treatment of a viral disease, notably of viral hepatitis
WO1999027133A1 (en) 1997-11-26 1999-06-03 Medical Research Council Improved selex procedure and an anti-cd4 aptamer
US6506559B1 (en) 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
US6180348B1 (en) 1998-04-20 2001-01-30 Weihua Li Method of isolating target specific oligonucleotide ligands
GB9827152D0 (en) 1998-07-03 1999-02-03 Devgen Nv Characterisation of gene function using double stranded rna inhibition
WO2000020040A1 (en) 1998-10-08 2000-04-13 University Of Massachusetts Controlling gene expression in living cells
AU776150B2 (en) 1999-01-28 2004-08-26 Medical College Of Georgia Research Institute, Inc. Composition and method for (in vivo) and (in vitro) attenuation of gene expression using double stranded RNA
DE19956568A1 (de) 1999-01-30 2000-08-17 Roland Kreutzer Verfahren und Medikament zur Hemmung der Expression eines vorgegebenen Gens
MY128897A (en) 1999-02-05 2007-02-28 Samsung Electronics Co Ltd Image texture retrieving method and apparatus thereof
EP1235842A4 (en) 1999-10-15 2003-04-23 Univ Massachusetts Rna interference pathway genes as tools for targeted genetic interference
GB9927444D0 (en) 1999-11-19 2000-01-19 Cancer Res Campaign Tech Inhibiting gene expression
AU2002368077B2 (en) 2001-07-12 2010-03-04 Jefferson Foote Super humanized antibodies
JP4906094B2 (ja) 2004-01-16 2012-03-28 リジェネロン・ファーマシューティカルズ・インコーポレイテッド レセプターを活性化し得る融合ポリペプチド
JP2008507288A (ja) 2004-07-23 2008-03-13 アクセルロン ファーマ インコーポレーテッド ＡｃｔＲＩＩ受容体ポリペプチド、方法、および組成物
US8128933B2 (en) 2005-11-23 2012-03-06 Acceleron Pharma, Inc. Method of promoting bone growth by an anti-activin B antibody
CL2007002567A1 (es) 2006-09-08 2008-02-01 Amgen Inc Proteinas aisladas de enlace a activina a humana.
TW201627320A (zh) 2007-02-02 2016-08-01 艾瑟勒朗法瑪公司 衍生自ＡｃｔＲＩＩＢ的變體與其用途
CA2699936A1 (en) 2007-09-18 2009-03-26 Acceleron Pharma Inc. Activin-actriia antagonists and uses for decreasing or inhibiting fsh secretion
JP5270913B2 (ja) 2007-12-26 2013-08-21 サンゴバン・ティーエム株式会社 高電気抵抗高ジルコニア鋳造耐火物
WO2009137075A1 (en) 2008-05-06 2009-11-12 Acceleron Pharma Inc. Anti-activin antibodies and uses for promoting bone growth
WO2014064292A1 (en) 2012-10-26 2014-05-01 Universite Pierre Et Marie Curie (Paris 6) A method for preventing or treating atrial fibrillation
TWI682941B (zh) 2013-02-01 2020-01-21 美商再生元醫藥公司 含嵌合恆定區之抗體
TWI655207B (zh) 2013-07-30 2019-04-01 再生元醫藥公司 抗活化素ａ之抗體及其用途
US9906799B2 (en) 2014-06-20 2018-02-27 Qualcomm Incorporated Copy from previous rows for palette mode coding

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170211070A1 (en) * 2014-03-31 2017-07-27 Sumitomo Dainippon Pharma Co., Ltd. Prophylactic Agent and Therapeutic Agent for Fibrodysplasia Ossificans Progressiva
CN107106648A (zh) * 2014-09-12 2017-08-29 瑞泽恩制药公司 进行性骨化性纤维发育不良的治疗

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
MATTHEW T. DRAKE等: "The Rare Bone DiseaseWorking Group: report from the 2016 American Society for Bone and Mineral Research Annual Meeting", BONE, vol. 102, 20 January 2017 (2017-01-20), pages 80 - 84 *
SARAH J. HATSELL等: "ACVR1R206H receptor mutation causes fibrodysplasia ossificans progressiva by imparting responsiveness to activin A", SCIENCE TRANSLATIONAL MEDICINE, vol. 7, no. 303, 2 September 2015 (2015-09-02), pages 303 *

Also Published As

Publication number Publication date
WO2021142191A1 (en) 2021-07-15
US12344665B2 (en) 2025-07-01
US20260103508A1 (en) 2026-04-16
US20210253685A1 (en) 2021-08-19
IL294611A (en) 2022-09-01
CL2022001861A1 (es) 2023-02-24
BR112022013589A2 (pt) 2022-09-13
CA3164168A1 (en) 2021-07-15
JP2023510270A (ja) 2023-03-13
EP4087652A1 (en) 2022-11-16
AU2021205929A1 (en) 2022-09-01
KR20220139886A (ko) 2022-10-17
MX2022008494A (es) 2022-10-10
IL294611B1 (en) 2026-05-01
JP7802672B2 (ja) 2026-01-20
JP2026031632A (ja) 2026-02-24

Similar Documents

Publication Publication Date Title
US11407822B2 (en) Treatment of fibrodysplasia ossificans progressiva
US10689448B2 (en) Monoclonal antibodies to fibroblast growth factor receptor 2
US9617337B2 (en) Siglec-15 antibodies in treating bone loss-related disease
JP2026031632A (ja) 進行性骨化性線維異形成症の治療
EA050977B1 (ru) Способ снижения или предупреждения образования новых поражений с гетеротопической оссификацией у субъектов с прогрессирующей оссифицирующей фибродисплазией (fop)
BR122025025191A2 (pt) Uso de uma quantidade terapeuticamente eficaz de um antagonista da ativina a no tratamento de fibrodisplasia ossificante progressiva
WO2020181080A1 (en) Biomarkers for treatment of cancer
HK1238260B (en) Treatment of fibrodysplasia ossificans progressiva
HK1238260A1 (en) Treatment of fibrodysplasia ossificans progressiva
EA039118B1 (ru) Способ лечения прогрессирующей оссифицирующей фибродисплазии
BR112017004812B1 (pt) Uso de um anticorpo contra ativina a para preparação de um medicamento para tratamento de fibrodisplasia ossificante progressiva

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination